UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 226

Sortiert nach

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

European journal of cancer (1990), 2021-12, Vol.159, p.144-153

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases

Investigational new drugs, 2021-12, Vol.39 (6), p.1598-1603

2021

Link zum Volltext

Verfügbarkeit prüfen

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50

Frontiers in immunology, 2024, Vol.15, p.1348034-1348034

2024

Link zum Volltext

Verfügbarkeit prüfen

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

Cancers, 2023-02, Vol.15 (5), p.1543

2023

Link zum Volltext

Verfügbarkeit prüfen

Osteopoikilosis Occurring in the Skull

Internal Medicine, 2016/10/01, Vol.55(19), pp.2907-2908

2016

Link zum Volltext

Verfügbarkeit prüfen

Primary Malignant Lymphoma Originating from the Chest Wall without Preceding Pleural Disease

Internal Medicine, 2017/03/15, Vol.56(6), pp.681-686

2017

Link zum Volltext

Verfügbarkeit prüfen

A Case of Limbic Encephalitis Presenting as Paraneoplastic Neurological Syndrome with Possible Involvement of Immune Checkpoint Inhibitors

Haigan, 2022/12/20, Vol.62(7), pp.1048-1055

2022

Link zum Volltext

Verfügbarkeit prüfen

Srv2/CAP is required for polarized actin cable assembly and patch internalization during clathrin-mediated endocytosis

Journal of cell science, 2016-01, Vol.129 (2), p.367-379

2016

Link zum Volltext

Verfügbarkeit prüfen

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

Diagnostics (Basel), 2021-11, Vol.11 (12), p.2170

2021

Link zum Volltext

Verfügbarkeit prüfen

A Case of Aspiration of High-molecular Polymer Sevelamer Hydrochloride That Caused Dyspnea

The Journal of the Japan Society for Respiratory Endoscopy, 2021/09/25, Vol.43(5), pp.510-514

2021

Link zum Volltext

Verfügbarkeit prüfen

Concomitant Systemic Sclerosis and Sarcoidosis with Combined Pulmonary Fibrosis and Emphysema

Internal Medicine, 2016, Vol.55(10), pp.1331-1335

2016

Link zum Volltext

Verfügbarkeit prüfen

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study

JTO clinical and research reports, 2024-03, Vol.5 (3), p.100644-100644, Article 100644

2024

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

JTO clinical and research reports, 2022-07, Vol.3 (7), p.100355-100355, Article 100355

2022

Link zum Volltext

Verfügbarkeit prüfen

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

JTO clinical and research reports, 2023-04, Vol.4 (4), p.100494-100494, Article 100494

2023

Link zum Volltext

Verfügbarkeit prüfen

傍腫瘍性神経症候群として発症し免疫チェックポイント阻害薬の関与が疑われた辺縁系脳炎の1例

肺癌, 2022/12/20, Vol.62(7), pp.1048-1055

2022

Link zum Volltext

Verfügbarkeit prüfen

PDGF-D/PDGF-ββ Receptor-Regulated Chemo-taxis of Malignant Mesothelioma Cells

Cellular physiology and biochemistry, 2012, Vol.29 (1-2), p.241-250

2012

Link zum Volltext

Verfügbarkeit prüfen

長期間無再発を維持するも7年後に左副腎転移を来した進展型肺小細胞癌の1例

肺癌, 2021/08/20, Vol.61(4), pp.347-352

2021

Link zum Volltext

Verfügbarkeit prüfen

P56-7 A case of Nuclear protein in testis (NUT) midline carcinoma with response to Ewing sarcoma-based chemotherapy regimen

Annals of oncology, 2021-07, Vol.32, p.S360-S360

2021

Link zum Volltext

Verfügbarkeit prüfen

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

Lung cancer (Amsterdam, Netherlands), 2021-11, Vol.161, p.86-93

2021

Link zum Volltext

Verfügbarkeit prüfen

MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC

Annals of oncology, 2023-11, Vol.34, p.S1397-S1397

2023

Link zum Volltext

Verfügbarkeit prüfen

MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis)

Annals of oncology, 2023-11, Vol.34, p.S1432-S1432

2023

Link zum Volltext

Verfügbarkeit prüfen

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Journal of thoracic oncology, 2022-08, Vol.17 (8), p.1002-1013

2022

Link zum Volltext

Verfügbarkeit prüfen

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

Lung cancer (Amsterdam, Netherlands), 2023-12, Vol.186, p.107426-107426, Article 107426

2023

Link zum Volltext

Verfügbarkeit prüfen

A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer

Anticancer research, 2020-05, Vol.40 (5), p.2981-2987

2020

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]

Lung cancer (Amsterdam, Netherlands), 2024-02, Vol.188, p.107450-107450, Article 107450

2024

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 226

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(191)
Mit Volltextzugriff
(214)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation–positive non–small-cell lung cancer in a real-world setting (OSI-FACT)

Phase 1b study of ramucirumab in combination with erlotinib or osimertinib for untreated EGFR-mutated non–small cell lung cancer patients with asymptomatic brain metastases

Prognostic impact of clinical factors for immune checkpoint inhibitor with or without chemotherapy in older patients with non-small cell lung cancer and PD-L1 TPS ≥ 50

Age-Stratified Analysis of First-Line Chemoimmunotherapy for Extensive-Stage Small Cell Lung Cancer: Real-World Evidence from a Multicenter Retrospective Study

Osteopoikilosis Occurring in the Skull

Primary Malignant Lymphoma Originating from the Chest Wall without Preceding Pleural Disease

A Case of Limbic Encephalitis Presenting as Paraneoplastic Neurological Syndrome with Possible Involvement of Immune Checkpoint Inhibitors

Srv2/CAP is required for polarized actin cable assembly and patch internalization during clathrin-mediated endocytosis

Prognostic Markers of Survival among Japanese Patients with Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer Receiving First-Line Alectinib

A Case of Aspiration of High-molecular Polymer Sevelamer Hydrochloride That Caused Dyspnea

Concomitant Systemic Sclerosis and Sarcoidosis with Combined Pulmonary Fibrosis and Emphysema

Comparing Three Different Anti–Programmed Death-Ligand 1 Antibodies in Immunohistochemical Evaluation of Combined Chemoimmunotherapy Response in Patients With NSCLC: A Prospective Study

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study

傍腫瘍性神経症候群として発症し免疫チェックポイント阻害薬の関与が疑われた辺縁系脳炎の1例

PDGF-D/PDGF-ββ Receptor-Regulated Chemo-taxis of Malignant Mesothelioma Cells

長期間無再発を維持するも7年後に左副腎転移を来した進展型肺小細胞癌の1例

P56-7 A case of Nuclear protein in testis (NUT) midline carcinoma with response to Ewing sarcoma-based chemotherapy regimen

Real-world survey of pneumonitis and its impact on durvalumab consolidation therapy in patients with non-small cell lung cancer who received chemoradiotherapy after durvalumab approval (HOPE-005/CRIMSON)

MO3-6 The elderly subgroup analysis in real world survey (CRIMSON) of concurrent chemoradiotherapy in locally advanced NSCLC

MO57-4 Association of Glasgow prognostic score with efficacy and safety of first-line osimertinib in EGFR mutated NSCLC (OSI-FACT exploratory analysis)

Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small cell lung cancer in a real-world setting (OSI-FACT-EP)

A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer

Corrigendum to "Osimertinib as first-line treatment for elderly patients with advanced EGFR mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT-EP)" [Lung Cancer 186 (2023) 107426]

Suchergebnisse filtern